Sensus Healthcare Inc - SRTS STOCK NEWS

Sensus Healthcare (Nasdaq: SRTS) announced a retrospective study revealing a keloid recurrence rate of only 10.4% at 12 months for patients treated with superficial radiation therapy (SRT) after keloidectomy, significantly lower than the typical rate of over 80% with surgical excision alone. This study, published in the Journal of Clinical and Aesthetic Dermatology, involved 61 subjects and highlighted SRT's effectiveness, confirming its potential as a game-changer for treating keloids. The Kaplan-Meier survival probability cure rate stood at 85.6% from 24 months post-treatment.

Sensus Healthcare, Inc. (SRTS) reported second quarter results for 2020, revealing revenues of $1.2 million, down from $7.5 million in Q2 2019, largely due to COVID-19 impacts. The company experienced a net loss of $2.6 million, or $0.16 per share, compared to a profit of $0.1 million a year prior. Cash reserves increased to $18.9 million. Recent strategic moves include acquiring two mobile laser companies in Florida, aiming to generate $1 million in base revenues over the next year, and expanding marketing efforts post-pandemic.

Sensus Healthcare (Nasdaq: SRTS) has acquired two mobile aesthetic laser companies, Aesthetic Mobile Laser Services and Aesthetic Laser Partners, significantly expanding its dermatology customer base in Florida. These acquisitions are anticipated to generate an additional $1.0 million in revenue over the next 12 months and are immediately accretive to earnings. The new division, Sensus Laser Aesthetic Solutions, will be led by management from the acquired companies, enhancing market reach and technology integration as Sensus plans to introduce its own aesthetic laser products.

Sensus Healthcare (Nasdaq: SRTS) will hold a conference call on August 6, 2020, at 4:30 p.m. ET to discuss its Q2 2020 financial results and provide a business update, including recent and upcoming milestones. Investors can access the call via dial-in numbers or a live webcast. The company specializes in non-invasive treatments for oncological and non-oncological conditions, highlighting its innovative products like the Sculptura™ system and SRT-100™ series, aimed at improving patient quality of life.

Sensus Healthcare (Nasdaq: SRTS) has announced the appointment of Hoi-Bun “Benson” Suen as Vice President of International Sales, focusing on the Southeast Asian market for Superficial Radiation Therapy (SRT) products. Mr. Suen's experience includes nearly 20 years in medical device sales in Asia, contributing to the successful shipment of an SRT-100 system to China. CEO Joe Sardano expressed confidence in Mr. Suen's abilities, highlighting potential growth in shipments of SRT-100 units. Sensus specializes in non-invasive treatment devices targeting oncological conditions.

Sensus Healthcare (Nasdaq: SRTS) announced that CEO Joe Sardano will present at the Re-Engaging Medical Practices in an Era of COVID-19 webinar on July 16, 2020. This event aims to discuss the reopening of medical practices post-COVID-19, exploring revenue recovery, patient engagement, and the adaptation of commercialization strategies. It will include Q&A sessions and panel discussions to share insights and strategies on navigating the changing healthcare landscape. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions.

Sensus Healthcare (Nasdaq: SRTS) announced that CEO Joe Sardano will participate in a panel discussion at the Fall Clinical Virtual Grand Rounds on June 30, 2020. The session is titled Directions in Dermatology and Their Impact on You: Patients, Practice and Pharma and focuses on superficial radiation therapy (SRT). This is part of a series aimed at providing continuing medical education (CME) to dermatologists during the pandemic. The event highlights Sensus’ commitment to supporting dermatology practices.

Sensus Healthcare, Inc. (Nasdaq: SRTS) announced that Dr. Jeffrey S. Fromowitz will discuss superficial radiation therapy at the Fall Clinical Virtual Grand Rounds today. This presentation will cover treatment for non-melanoma skin cancers and keloids, contributing to continuing medical education (CME) credits for participants. Dr. Fromowitz, a board-certified dermatologist, is affiliated with Dermatology of Boca and has advanced training in Mohs micrographic surgery. Sensus Healthcare specializes in non-invasive medical devices for oncological and non-oncological conditions.

Sensus Healthcare (Nasdaq: SRTS) is hosting a program titled "Medical-Legal Issues in the Era of COVID-19" on June 18 at 3:00 p.m. ET. This event is part of a series aimed at discussing the role of superficial radiation therapy (SRT) amidst the pandemic. Hosted by CEO Joe Sardano and Dr. David Goldberg, the session addresses malpractice protections, employment issues, and telemedicine applications for SRT patients. The successful response to earlier events indicates strong interest in these discussions.